LOGIN  |  REGISTER
Astria Therapeutics
Amneal Pharmaceuticals

Sirona Biochem: Stonegate Healthcare Partners Announces Publication of Thematic Report on Anti-Aging Dermatology Innovations

June 18, 2024 | Last Trade: C$0.07 0.00 0.00

Dallas, Texas--(Newsfile Corp. - June 18, 2024) - Stonegate Healthcare Partners, a leading name in healthcare consultancy and market intelligence, is pleased to announce the publication of a comprehensive thematic report titled "Leading Innovations in Anti-Aging Dermatology." This report delves into the transformative advancements in the treatment of age-related skin conditions, focusing on cutting-edge technologies and personalized holistic approaches that are poised to revolutionize the skincare industry.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • Emerging novel topicals: Innovations like OneSkin's OS-01, Sirona Biochem's GlycoProteMim, and SK-II's Pitera offer signficant benefits that will let them take market share away from existing treatments.
  • Personalized and holistic skincare: Advances ingenomics, skin diagnostics, and AI-driven tools enable tailored treatment plans ushering in a new era of skincare.
  • Companies highlighted in this report are: SkinMedica, SK-II, Sirona Biochem (TSXV: SBM), One Skin, and CTEK Sisley.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/7294/213432_figure1_550.jpgAbout Stonegate Healthcare Partners

Our mission at Stonegate Healthcare Partners is to accelerate meaningful innovations in healthcare through Strategy, Market Intelligence, Business Development, and Investor Outreach. The firm's research approach is centered on comprehensive and comparative analyses in specific healthcare fields. We strive to pinpoint programs that align closely with our strategic vision for the space and focus on technologies with the greatest potential for disruption. Stonegate Healthcare builds on its foundational thematic research by continuously gathering market intelligence, further enabling a current understanding of unmet needs and emerging disruptive technologies. 

Contacts:

Shiv Kapoor
This email address is being protected from spambots. You need JavaScript enabled to view it.

Source: Stonegate Healthcare

C4 Therapeutics

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page